Sol-Gel Technologies Ltd. (SLGL)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 400K | 696K | 108K | 591K |
| Operating Income | (6.3M) | (3.4M) | (3.9M) | (4.2M) |
| Net Income | (5.9M) | (3.0M) | (3.7M) | (3.7M) |
| Diluted EPS | $-2.13 | N/A | $-1.31 | $-1.13 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 3.9M | 1.6M | 11.5M | 19.4M |
| Operating Income | (16.2M) | (29.3M) | (12.0M) | (7.5M) |
| Net Income | (14.9M) | (27.2M) | (10.6M) | (6.1M) |
| Diluted EPS | $-6.50 | $-10.01 | $-3.79 | $-2.19 |